close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

63.11 +0.37 (+0.59%)
Streaming Delayed Price Updated: 3:43 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exact Sciences Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
3 Unprofitable Stocks with Questionable Fundamentals
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth. 
Via StockStory
3 Cash-Producing Stocks We Think Twice About
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
Exact Sciences Presents New Findings at ACG 2025 Demonstrating How the Cologuard Test Helps Improve Adherence and Close Screening Gaps
From Exact Sciences Corp.
Via Business Wire
11 Analysts Have This To Say About Exact Sciences
 
Via Benzinga
Immuno-Oncology Stocks Q2 Recap: Benchmarking Exact Sciences (NASDAQ:EXAS)
Looking back on immuno-oncology stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Exact Sciences (NASDAQ:EXAS) and its peers. 
Via StockStory
Topics Artificial Intelligence
3 High-Flying Stocks We Steer Clear Of
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated... 
Via StockStory
Topics Firearms
Exact Sciences Schedules Third Quarter 2025 Earnings Call
From Exact Sciences Corp.
Via Business Wire
New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest Colonoscopies
From Exact Sciences Corp.
Via Business Wire
What Analysts Are Saying About Exact Sciences Stock
 
Via Benzinga
Decoding Life's Blueprint: New Tech Maps RNA-Protein Interactions, Unlocking Disease Cures
A monumental leap in biomedical research has been announced with the development of a breakthrough technology capable of mapping the entire intricate network of RNA-protein interactions within human... 
Via MarketMinute
Topics Artificial Intelligence Derivatives
Exact Sciences (EXAS) Stock Trades Up, Here Is Why
Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) jumped 2.2% in the afternoon session after the Nancy Gardner Sewell MCED Act advanced in the U.S. House, a development that could... 
Via StockStory
Horror Icon Matthew Lillard and Exact Sciences Help Adults 45+ Conquer Fear and Get Screened for Colon Cancer with the Cologuard® Test
From Exact Sciences Corp.
Via Business Wire
Peering Into Exact Sciences's Recent Short Interest
 
Via Benzinga
Demystifying Exact Sciences: Insights From 9 Analyst Reviews
 
Via Benzinga
Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test
From Exact Sciences Corp.
Via Business Wire
Wayfair, United Therapeutics, And Ciena Are Among The Top 10 Large-Cap Gainers Last Week (July 14-July 18): Are The Others In Your Portfolio?
These ten large-cap stocks were top performers last week. Are they a part of your portfolio? 
Via Benzinga
Why Exact Sciences (EXAS) Stock Is Trading Up Today
Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) jumped 6.3% in the afternoon session after extending its positive momentum as RBC Capital Markets raised its price target on the... 
Via StockStory
Why IBD 50's Guardant Health Just Tumbled, Breaking A 67% Monthlong Run
The company is working on a second version of its colon cancer screening test, Shield. 
Via Investor's Business Daily
Immuno-Oncology Q2 Earnings: Regeneron (NASDAQ:REGN) Simply the Best
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
Exact Sciences (EXAS) Stock Trades Up, Here Is Why
Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) jumped 1.5% in the afternoon session after RBC Capital Markets raised its price target on the company. The investment bank... 
Via StockStory
Topics Artificial Intelligence Economy
3 of Wall Street’s Favorite Stocks We’re Skeptical Of
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
Exact Sciences to Participate in September Investor Conferences
From Exact Sciences Corp.
Via Business Wire
3 Unprofitable Stocks We Think Twice About
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital... 
Via StockStory
Sotera Health Company, Incyte, Exact Sciences, Bausch + Lomb, and Addus HomeCare Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Economy Lawsuit
1 Small-Cap Stock to Own for Decades and 2 We Turn Down
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
Micron To Rally More Than 49%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
EXAS Q2 Deep Dive: Portfolio Expansion and Productivity Drive Guidance Increase Amid Market Caution
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue in Q2 CY2025, with sales up 16% year on year to $811.1 million. The company’s full-year revenue... 
Via StockStory
3 Out-of-Favor Stocks We Steer Clear Of
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds. 
Via StockStory
Topics Supply Chain
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The rock-star money manager is making the most of sell-offs in some of her stocks. 
Via The Motley Fool
Beyond The Numbers: 7 Analysts Discuss Exact Sciences Stock
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today